Education
About Us
Working with TipRanks
Follow Us
Pharmaron Beijing Co., Ltd. Class H (HK:3759)
:3759
3759 Stock Chart & Stats
HK$24.14
HK$0.24(1.88%)
At close: 4:00 PM EST
HK$24.14
HK$0.24(1.88%)
Day’s Range― - ―
52-Week RangeHK$10.46 - HK$30.12
Previous CloseN/A
Volume1.90M
Average Volume (3M)3.76M
Market Cap
HK$56.54B
Enterprise ValueHK$49.36B
Total Cash (Recent Filing)HK$2.28B
Total Debt (Recent Filing)HK$6.39B
Price to Earnings (P/E)22.5
Beta2.02
Next Earnings
Mar 30, 2026EPS Estimate
0.31Next Dividend Ex-DateN/A
Dividend Yield1.04%
Share Statistics
EPS (TTM)0.27
Shares Outstanding359,977,870
10 Day Avg. Volume3,469,725
30 Day Avg. Volume3,761,430
Financial Highlights & Ratios
PEG Ratio13.20
Price to Book (P/B)1.74
Price to Sales (P/S)1.93
P/FCF Ratio44.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Integrated CRDMO Business ModelAn end-to-end CRDMO model creates durable demand as clients outsource from discovery through manufacturing. That breadth increases stickiness, enables multi-stage contracts as programs progress, and diversifies revenue sources, supporting steady long-term service demand and client retention.
Sustained Revenue ExpansionConsistent top-line growth (mid-teens on recent metric and material scaling over the cycle) signals persistent client demand and successful business development. Durable revenue expansion supports capacity utilization, strategic reinvestment, and a pathway to larger, longer-duration development and manufacturing contracts.
Improved Leverage And Growing EquityMarked reduction in leverage and steady equity growth enhances financial flexibility and resilience. Lower debt-to-equity reduces refinancing and liquidity risk, enabling sustained capex, strategic investments or deal activity without overburdening cash flow during industry cycles.
Bears Say
Margin Compression And Earnings Step-DownSignificant margin erosion over the cycle materially reduces profitability per revenue dollar. Lower net margins and a step-down in earnings suggest structural pressure (pricing, mix, or cost increases) that can persist, weakening internal cash generation and long-run returns unless operational efficiencies are regained.
Volatile And Subscale Free Cash FlowIrregular and relatively low free cash flow versus earnings constrains the firm's ability to self-fund growth, pay down debt or return capital. Persistent FCF volatility—driven by working-capital swings or reinvestment—raises dependence on external funding and increases long-term financial risk.
Eroding Return On EquityDeclining ROE indicates new invested capital is delivering weaker returns than prior periods. If sustained, lower profitability on a larger equity base limits shareholder value creation, signals potential competitive or execution challenges, and reduces the leverage benefit from balance-sheet expansion.
Pharmaron Beijing Co., Ltd. Class H News
3759 FAQ
What was Pharmaron Beijing Co., Ltd. Class H’s price range in the past 12 months?
Pharmaron Beijing Co., Ltd. Class H lowest stock price was HK$10.46 and its highest was HK$30.12 in the past 12 months.
What is Pharmaron Beijing Co., Ltd. Class H’s market cap?
Pharmaron Beijing Co., Ltd. Class H’s market cap is HK$56.54B.
When is Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date?
Pharmaron Beijing Co., Ltd. Class H’s upcoming earnings report date is Mar 30, 2026 which is in 36 days.
How were Pharmaron Beijing Co., Ltd. Class H’s earnings last quarter?
Pharmaron Beijing Co., Ltd. Class H released its earnings results on Oct 28, 2025. The company reported HK$0.272 earnings per share for the quarter, missing the consensus estimate of HK$0.273 by -HK$0.001.
Is Pharmaron Beijing Co., Ltd. Class H overvalued?
According to Wall Street analysts Pharmaron Beijing Co., Ltd. Class H’s price is currently Overvalued.
Does Pharmaron Beijing Co., Ltd. Class H pay dividends?
Pharmaron Beijing Co., Ltd. Class H pays a Annually dividend of HK$0.219 which represents an annual dividend yield of 1.04%. See more information on Pharmaron Beijing Co., Ltd. Class H dividends here
What is Pharmaron Beijing Co., Ltd. Class H’s EPS estimate?
Pharmaron Beijing Co., Ltd. Class H’s EPS estimate is 0.31.
How many shares outstanding does Pharmaron Beijing Co., Ltd. Class H have?
Pharmaron Beijing Co., Ltd. Class H has 359,977,870 shares outstanding.
What happened to Pharmaron Beijing Co., Ltd. Class H’s price movement after its last earnings report?
Pharmaron Beijing Co., Ltd. Class H reported an EPS of HK$0.272 in its last earnings report, missing expectations of HK$0.273. Following the earnings report the stock price went down -1.188%.
Which hedge fund is a major shareholder of Pharmaron Beijing Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3759
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharmaron Beijing Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
10.94%
Trailing 12-Months
Asset Growth
2.48%
Trailing 12-Months
Company Description
Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. Class H (3759) is a leading contract research organization (CRO) offering a comprehensive range of R&D and manufacturing services to the pharmaceutical and biotechnology sectors. Founded in Beijing, China, Pharmaron provides integrated services in discovery, development, and manufacturing, covering various stages of drug research and production. The company's core services include drug discovery, preclinical research, clinical development, and commercial manufacturing, serving clients across the globe.
Technical Analysis
Genscript Biotech
―
Zai Lab Ltd
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---